In an interview with “Der Aktionär”, Formycon CFO Enno Spillner talks about the development of the Lucentis® biosimilar FYB201/Cimerli® in the US, the company’s operational targets for 2024 and what is unique about Formycon as a pure-play biosimilar developer. The interview was conducted by Michel Doepke. Learn more …

      

SocialMedia